"German Drug Development Company Says Cyberattack Causing Production Delays"

Evotec is still recovering from a cyberattack that forced it to shut down its Information Technology (IT) systems. The cyberattack prompted the disconnection of their systems from the Internet to prevent data corruption or breaches. In a recent update, the company stated that cybersecurity experts and others are conducting a forensic examination of its systems. Evotec has also informed German law enforcement agencies of the attack. Evotec has over 4,200 employees and generated nearly $700 million in revenue in 2021 by developing pharmaceuticals to treat Alzheimer's, Huntington's disease, and other diseases. The company has long-term partnerships with Bristol Myers Squibb, Bayer, Sanofi, and other pharmaceutical titans for drug discovery. Evotec has not yet reconnected its network, but all of its global locations have maintained business continuity, according to the company. This article continues to discuss the cyberattack on the German drug development giant Evotec. 

The Record reports "German Drug Development Company Says Cyberattack Causing Production Delays"